Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-29T23:35:01.391Z Has data issue: false hasContentIssue false

Association between cannabis use and symptoms of psychosis: a mega-analysis

Published online by Cambridge University Press:  19 July 2023

M. Argote*
Affiliation:
PSYR2 team, CH Le Vinatier, Lyon
B. Rolland
Affiliation:
PSYR2 team, CH Le Vinatier, Lyon
G. Sescousse
Affiliation:
PSYR2 team, CH Le Vinatier, Lyon
J. Brunelin
Affiliation:
PSYR2 team, CH Le Vinatier, Lyon
E. Fakra
Affiliation:
Pôle universitaire de psychiatrie, CHU Saint-Etienne, Saint-Etienne
M. Nourredine
Affiliation:
Service de biostatistiques, Hospices civiles de Lyon, Lyon
R. Jardri
Affiliation:
Centre Hospitalier de Lille, Lille, France
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

It remains debated in the scientific literature whether cannabis aggravates psychotic symptoms or is used as a self-medication. Regular cannabis use (RCU) was found associated with the severity of positive symptoms of psychosis i.e., delusion or hallucinations. However, the association with negative symptoms, i.e. blunted affect or social withdrawal, is less straightforward. Confounding variables such as the criteria for other Substance Use Disorders (SUDs), illness duration, or socio-demographic features can interfere with the appraisal of effect of RCU on these symptoms. Studies are rarely adjusted for these variables and no adjustment can be performed in meta-analyses which use aggregated data. For these reasons, we decided to conduct a mega-analysis based on individual patient data (IPD) allowing to control for theses variables and isolate the specific association between RCU and the severity of symptoms.

Objectives

Investigate the association between RCU on the positive, negative, general, and disorganized symptoms of psychosis as assessed by the Positive and Negative Syndrome Scale (PANSS), accounting for individual-level confounding variables.

Methods

IPD were requested by email to corresponding authors of published articles that measured RCU and PANSS scores in subjects with schizophrenia-spectrum disorders, based on a screening process on PubMed, ScienceDirect and PsycINFO databases. A two-stage random effect multivariate IPD meta-analysis was then performed, to isolate the direct association between RCU and the ‘positive’, ‘negative’, and ‘general’ dimensions of schizophrenia-spectrum disorders. Confounding variables were included in the models when available in the original dataset.

Results

65 publications were eligible for inclusion. 18 authors agreed to provide their IPD. A total of 16 datasets were usable, regrouping 3,346 individual participant data, with 2,827 complete cases. Regression coefficients extracted after the first stage were adjusted for at least sex and age across all studies. RCU was found to be significantly associated with heightened positive symptoms severity (MD = 0.41, 95% CI [0.0; 0.82], p = 0.04), whereas it appeared significantly associated with less severe negative symptoms (MD = -0.63, 95% CI [-1.1; -0.17], p = 0.008). No significant association was found between RCU and general symptoms (MD = -0.24, 95% CI [-069; 0.21]; p = 0.29), as well as disorganization (MD = -0.08, 05%CI [-0.47; 0.35], p = 0.63).

Conclusions

Our results allow for a general and subtle overview of the association of RCU with symptoms of psychosis. Our findings suggest a double and paradoxical effect of cannabis, which could both exacerbate positive symptoms and alleviate negative symptoms. This supports both the hypotheses of a disease aggravator and self-medication.

Results change as we receive datasets from collaborating authors and could continue to change as not all authors sent their datasets yet.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.